Transgenic Group Inc.

TSE:2342 Stock Report

Market Cap: JP¥3.7b

Transgenic Group Past Earnings Performance

Past criteria checks 0/6

Transgenic Group's earnings have been declining at an average annual rate of -62.4%, while the Biotechs industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 2.2% per year.

Key information

-62.44%

Earnings growth rate

-62.27%

EPS growth rate

Biotechs Industry Growth31.91%
Revenue growth rate2.24%
Return on equity-2.01%
Net Margin-0.58%
Next Earnings Update12 Aug 2026

Recent past performance updates

Recent updates

Analysis Article • Jan 15

Is Transgenic Group (TSE:2342) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Nov 19

Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/S

With a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) may be sending very bullish signals...
Analysis Article • Jun 17

Here's Why Transgenic Group (TSE:2342) Can Afford Some Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 17

There's No Escaping Transgenic Group Inc.'s (TSE:2342) Muted Revenues Despite A 33% Share Price Rise

Transgenic Group Inc. ( TSE:2342 ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Apr 15

Little Excitement Around Transgenic Group Inc.'s (TSE:2342) Revenues

Transgenic Group Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right...
Analysis Article • Nov 13

Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its Revenues

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) is definitely a...
Analysis Article • Apr 27

Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their Feet

Trans Genic Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy right now...

Revenue & Expenses Breakdown

How Transgenic Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:2342 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2613,174-772,2950
31 Dec 2512,893-7702,3260
30 Sep 2512,918-8782,3530
30 Jun 2513,320-9642,3830
31 Mar 2513,005-1,0892,4220
31 Dec 2413,147-2492,3640
30 Sep 2413,017-2262,2910
30 Jun 2412,685-1732,2170
31 Mar 2413,08342,1460
31 Dec 2312,708-6292,1460
30 Sep 2312,264-4152,1190
30 Jun 2312,239-3062,0800
31 Mar 2311,429-4092,0190
31 Dec 2211,3951,2561,9880
30 Sep 2211,4169492,0130
30 Jun 2211,7331,2431,9920
31 Mar 2212,5761,8761,9980
31 Dec 2112,8339002,0510
30 Sep 2113,0681,5021,9610
30 Jun 2112,1521,1641,9290
31 Mar 2111,0465461,8810
31 Dec 2011,012311,7640
30 Sep 2010,535-3741,7100
30 Jun 2010,902-3651,6430
31 Mar 2011,046-4401,6050
31 Dec 1910,1441741,4460
30 Sep 199,5411331,3720
30 Jun 198,9321331,3120
31 Mar 198,6742021,2280
31 Dec 188,607971,2310
30 Sep 187,0701211,0850
30 Jun 185,355539180
31 Mar 183,601207590
31 Dec 172,178166190
30 Sep 172,172295930
30 Jun 172,247685860
31 Mar 172,302805940
31 Dec 162,4881275970
30 Sep 162,524966080
30 Jun 162,378506200
31 Mar 162,290146220
31 Dec 152,1412558640
30 Sep 151,9924359740

Quality Earnings: 2342 is currently unprofitable.

Growing Profit Margin: 2342 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2342 is unprofitable, and losses have increased over the past 5 years at a rate of 62.4% per year.

Accelerating Growth: Unable to compare 2342's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2342 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.7%).

Return on Equity

High ROE: 2342 has a negative Return on Equity (-2.01%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/14 10:57
End of Day Share Price 2026/07/14 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Transgenic Group Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.